Sleepiness Could Be Triggered by a Power Overload in Our Brain
Researchers from the University of Oxford in the UK have identified our cell's mitochondria as responsible for signaling when the body has to get some shut-eye as soon as possible.
These tiny power generators cause a kind of metabolic overload in sleep-regulating neurons, the researchers suggest, which in simple terms indicates when our brain is running on empty. Through sleep, this overload can be reset, ensuring the brain remains in a healthy state.
Related:
"We set out to understand what sleep is for, and why we feel the need to sleep at all," says physiologist Gero Miesenböck. "Despite decades of research, no one had identified a clear physical trigger."
"Our findings show that the answer may lie in the very process that fuels our bodies: aerobic metabolism."
The team studied neurons responsible for regulating sleep in fruit flies, which have enough biological similarities to humans to make them useful for research. Through a comparison of well-rested and sleep-deprived fruit flies, the researchers identified differences in gene activity and electrical signaling.
Overloaded mitochondria in sleep-deprived brains were found to shed electrons, increasing the generation of harmful waste products. The sleep-regulating neurons respond to these molecules by going into overdrive, making sleep a top biological priority.
"You don't want your mitochondria to leak too many electrons," says neuroscientist Raffaele Sarnataro. "When they do, they generate reactive molecules that damage cells."
Genetically engineering flies with a higher production of electrons in their sleep-regulating cells resulted in fruit flies that also slept more. Similarly, flies with a reduced level of electron generation slept less.
There are, of course, other pressures on sleep, from how many coffees you have per day to the alignment of your circadian rhythm – the internal schedule that tells your body when it's time for bed. But now we have an actual cellular mechanism controlling sleep, and showing why we can't do without it.
Anything new we learn about sleep can inform the treatment of sleep disorders and even neurological conditions such as Alzheimer's. These diseases are closely linked to sleep and the way it protects the brain, and connections to mitochondria could be something for future studies to investigate.
The study also joins some of the dots between metabolism, sleep, and lifespan. Smaller animals tend to sleep more and live shorter lives, and the activity of mitochondria – and the waste that needs clearing up – could be part of the reason why.
"This research answers one of biology's big mysteries," says Sarnataro. "Why do we need sleep? The answer appears to be written into the very way our cells convert oxygen into energy."
The research has been published in Nature.
Related News
Study Reveals Key Way to Slow Chronic Illness in Old Age
Liver Cancer Predicted to Double by 2050, But There Is Hope
One Weekend Habit May Cut Risk of Heart-Related Death by 33%, Study Finds
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 days ago
- Politico
Senate appropriators defend the NIH
WASHINGTON WATCH Senate appropriators came out hard in support of the National Institutes of Health on Thursday, giving the agency a $400 million funding boost for the 2026 fiscal year. How so: The Senate Appropriations Committee upped the agency's budget to $48.7 billion in the 2026 funding bill that cleared the panel with a 26-3 vote Thursday. If the bill becomes law, it would increase cancer research by $150 million; Alzheimer's research by $100 million and amyotrophic lateral sclerosis, or ALS, research by $25 million. The NIH's National Institute of Allergy and Infectious Diseases and the Office of Research on Women's Health would each get a $30 million boost. Research on maternal mortality, diabetes and rare diseases would also see an increase, among others. Why it matters: The funding boost is a rebuke from both Republicans and Democrats to the Trump administration's demand to decrease the NIH funding in the next fiscal year by as much as 40 percent, or $18 billion. Senate Appropriations Chair Susan Collins (R-Maine) said the legislation 'prioritizes funding to help make Americans healthier and supports life-saving medical research.' Sen. Patty Murray (D-Wash.), the top Democrat on the panel, said the budget increase was a message to 'the scientists wondering if there will even be an NIH by the end of this administration. This committee's resounding message is: 'Yes, Congress has your back.'' Murray urged scientists to continue their research in the U.S. despite the efforts of other countries to lure them away. The appropriators also adopted an amendment Thursday that would limit the Trump administration's control over NIH research funding. An amendment in the bill's manager's package limits the administration's plan to shift funding for most NIH grants from a multiyear schedule to an upfront single-year payment. The amendment states that no funds appropriated in the fiscal 2026 spending bill can be used to increase the proportion of grants fully funded in the first year of the award, compared with fiscal 2024. The NIH can only increase that proportion of forward-funded grants if the agency ensures it isn't cutting grants to do so. What's next: The bill is cleared for floor action. But congressional leaders haven't started bipartisan negotiations toward overall government funding totals, increasing the odds that lawmakers will again resort to a stopgap funding patch before the next fiscal year starts on Oct. 1. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Peacock feathers have reflective structures that can amplify light into a laser beam, Science reports. Share any thoughts, news, tips and feedback with Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: CarmenP.82, RuthReader.02 or ErinSchumaker.01. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs, or court rulings could ripple through the economy? Start here. WORLD VIEW A draft United Nations plan to make the world healthier no longer includes several targets cracking down on sugary drinks, trans fats and tobacco to prevent and control noncommunicable diseases globally. Struck down: A target of 80 percent of countries taxing sugary drinks at levels recommended by the World Health Organization by 2030, POLITICO's Rory O'Neill reports. That goal was a pillar of the initial draft, which will take the form of a nonbinding political declaration world leaders are expected to endorse at a Sept. 25 meeting in New York, on the margins of the U.N. General Assembly. The latest version has also dropped commitments to eliminate trans fats and aims instead to reduce them to the 'lowest level possible.' It also requires front-of-pack labels with nutritional information. A requirement for health warnings on tobacco packaging to be graphic and accompanied by elements that make it unattractive to consumers is also gone. The new draft has softer language on tobacco advertising, requiring countries to restrict it instead of eliminate it. 'Make no mistake, the Declaration in its current form is a backslide,' said Alison Cox, director of policy and advocacy at the NCD Alliance, in a statement. The alliance is a Switzerland-based civil society group working to promote chronic disease prevention. Why it matters: World leaders aim to reduce premature mortality from noncommunicable diseases such as heart disease, cancer and diabetes by 2030 through prevention and treatment and to improve mental health and well-being globally. Noncommunicable diseases killed 18 million people under age 70 in 2021, according to the WHO. Most deaths were in low- and middle-income countries. The aims align with the U.S. Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda, but it's unclear how much the U.S. is involved in drafting the final text. HHS did not respond to a request for comment. What's next: Negotiators are meeting this week in New York to discuss the text.
Yahoo
3 days ago
- Yahoo
Three factors will stall dementia and the aging process, according to new U.S. study
By 2050, over 1.7 million Canadians are projected to be living with dementia. This represents an increase of 187 per cent compared to 2020, when approximately 597,300 Canadians were living with dementia, according to the Alzheimer's Society of Canada. Dementia describes the decline of mental ability, while Alzheimer's Disease is the medical term for the brain disease that commonly causes dementia. Researchers are now saying certain lifestyle changes can stave off mental decline. A new U.S. study sets out what Alzheimer's researchers are calling the strongest evidence yet regarding what is involved in slowing the aging process and improving cognition. It comes down to three key factors: a diet heavy on leafy greens, berries and grains, regular moderate exercise and ongoing social interaction. Regular cardiovascular monitoring is also a factor. Jessica Langbaum, senior director of research strategy at the Banner Alzheimer's Institute in Phoenix was not involved directly in the research but she presented the findings at an annual conference of experts in Toronto on Wednesday. The Alzheimer's Association International Conference (AAIC) is the largest international meeting dedicated to advancing dementia science and clinical practice. This year's gathering brought together 8,000 scientists and clinicians from all over the world, with the goal of improving diagnosis, risk reduction and treatment. The study pulled together diet, exercise and socialization in one substantial, structured study of 2,100 people in their 60s and 70s at risk of developing dementia, showing that bad habits 'can really slow down memory and thinking' in adults at risk for cognitive impairment and dementia, Langbaum told the PBS New Hour in an interview on Wednesday evening. The subjects who participated in the study changed their habits, shifting from a sedentary lifestyle to an active one and improving their diet over a two-year period, resulting in cognitive function scores on par with people one or two years younger. That might not sound like much, but Langbaum says the results are significant evidence that change can occur without medication. 'And so, it's showing that we can change the trajectory of aging,' she said. There were two groups in the study. In one, lifestyle changes were structurally prescribed. In the other, the changes were self-directed. The results for the prescribed group were much better, but Langbaum says both groups showed improvement. The biggest challenge that study participants faced was sustaining a new exercise regime. Langbaum recommends people find something that they enjoy doing. 'If (you're) frustrated by it, (you're) just going to give up. But do something that you enjoy. Better yet, do it with somebody else or others around you because socialization is key, and lastly, something that you can adhere to, if you can schedule it. It's something that you can stay committed to.' Regarding nutrition she notes: 'We say what's good for the heart is good for the brain, so a nice balanced … nutritious diet with … those leafy greens, low in saturated fats, all of those things.' The American Alzheimer's Association spent close to US$50 million on the study. The National Institutes of Health spent even more to ensure many of the participants underwent brain scans, blood tests and sleep studies aimed at provide additional information down the road. Meanwhile, Langbaum expresses concern that structured intervention may not be sustainable in most communities. 'I think that's really the next stage of the research is, how do we make this scalable in communities so that people can implement these things into their daily lives?' The American Alzheimer's Association is planning to spend another US$40 million on implementing the lessons of the study. Langbaum says that will come with a change in the mindsets of doctors. They 'should be treating lifestyle interventions as they would a drug,' she told NPR. That would mean prescribing improved exercise and eating regimens and getting insurers to cover those prescriptions, she added. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
WIRED
3 days ago
- WIRED
The First Widespread Cure for HIV Could Be in Children
Aug 1, 2025 9:19 AM Evidence is growing that some HIV-infected infants, if given antiretroviral drugs early in life, are able to suppress their viral loads to undetectable levels and then come off the medicine. An ARV tablet being held in Kisumu, Kenya, on April 24, 2025. Photograph:For years, Philip Goulder has been obsessed with a particularly captivating idea: In the hunt for an HIV cure, could children hold the answers? Starting in the mid-2010s, the University of Oxford pediatrician and immunologist began working with scientists in the South African province of KwaZulu-Natal, with the aim of tracking several hundred children who had acquired HIV from their mothers, either during pregnancy, childbirth, or breastfeeding. After putting the children on antiretroviral drugs early in their lives to control the virus, Goulder and his colleagues were keen to monitor their progress and adherence to standard antiretroviral treatment, which stops HIV from replicating. But over the following decade, something unusual happened. Five of the children stopped coming to the clinic to collect their drugs, and when the team eventually tracked them down many months later, they appeared to be in perfect health. 'Instead of their viral loads being through the roof, they were undetectable,' says Goulder. 'And normally HIV rebounds within two or three weeks.' In a study published last year, Goulder described how all five remained in remission, despite having not received regular antiretroviral medication for some time, and in one case, up to 17 months. In the decades-long search for an HIV cure, this offered a tantalizing insight: that the first widespread success in curing HIV might not come in adults, but in children. At the recent International AIDS Society conference held in Kigali, Rwanda, in mid-July, Alfredo Tagarro, a pediatrician at the Infanta Sofia University Hospital in Madrid, presented a new study showing that around 5 percent of HIV-infected children who receive antiretrovirals within the first six months of life ultimately suppress the HIV viral reservoir—the number of cells harboring the virus's genetic material—to negligible levels. 'Children have special immunological features which makes it more likely that we will develop an HIV cure for them before other populations,' says Tagarro. His thoughts were echoed by another doctor, Mark Cotton, who directs the children's infectious diseases clinical research unit at the University of Stellenbosch, Cape Town. 'Kids have a much more dynamic immune system,' says Cotton. 'They also don't have any additional issues like high blood pressure or kidney problems. It makes them a better target, initially, for a cure.' According to Tagarro, children with HIV have long been 'left behind' in the race to find a treatment that can put HIV-positive individuals permanently into remission. Since 2007, 10 adults are thought to have been cured, having received stem cell transplants to treat life-threatening blood cancer, a procedure which ended up eliminating the virus. Yet with such procedures being both complex and highly risky—other patients have died in the aftermath of similar attempts—it is not considered a viable strategy for specifically targeting HIV. Instead, like Goulder, pediatricians have increasingly noticed that after starting antiretroviral treatment early in life, a small subpopulation of children then seem able to suppress HIV for months, years, and perhaps even permanently with their immune system alone. This realization initially began with certain isolated case studies: the 'Mississippi baby' who controlled the virus for more than two years without medication, and a South African child who was considered potentially cured having kept the virus in remission for more than a decade. Cotton says he suspects that between 10 and 20 percent of all HIV-infected children would be capable of controlling the virus for a significant period of time, beyond the typical two to three weeks, after stopping antiretrovirals. Goulder is now launching a new study to try and examine this phenomenon in more detail, taking 19 children in South Africa who have suppressed HIV to negligible levels on antiretrovirals, stopping the drugs, and seeing how many can prevent the virus from rebounding, with the aim of understanding why. To date, he says that six of them have been able to control the virus without any drugs for more than 18 months. Based on what he's seen so far, he has a number of ideas about what could be happening. In particular, it appears that boys are more likely to better control the virus due to a quirk of gender biology to do with the innate immune system, the body's first-line defense against pathogens. 'The female innate immune system both in utero and in childhood is much more aggressive than the male equivalent when it encounters and senses viruses like HIV,' says Goulder. 'Usually that's a good thing, but because HIV infects activated immune cells, it actually seems to make girls more vulnerable to being infected.' In addition, Goulder notes that because female fetuses share the same innate immune system as their mothers, the virus transmitted to them is an HIV strain that has become resistant to the female innate immune response. There could also be other explanations for the long-lasting suppression seen in some children. In some cases, Goulder has observed that the transmitted strain of HIV has been weakened through needing to undergo changes to circumvent the mother's adaptive immune response, the part of the immune system which learns to target specific viruses and other pathogens. He has also noted that male infants experience particularly large surges of testosterone in the first six months of life—a period known as 'mini-puberty'—which can enhance their immune system in various ways that help them fight the virus. Such revelations are particularly tantalizing as HIV researchers are starting to get access to a far more potent toolbox of therapeutics. Leading the way are so-called bNAbs, or broadly neutralizing antibodies, which have the ability to recognize and fight many different strains of HIV, as well as stimulating the immune system to destroy cells where HIV is hiding. There are also a growing number of therapeutic vaccines in development that can train the immune system's T cells to target and destroy HIV reservoirs. Children tend to respond to various vaccines better than adults, and Goulder says that if some children are already proving relatively adept at controlling the virus on the back of standard antiretrovirals, these additional therapeutics could give them the additional assistance they need to eradicate HIV altogether. In the coming years, this is set to be tested in several clinical trials. Cotton is leading the most ambitious attempt, which will see HIV-infected children receive a combination of antiretroviral therapy, three bNAbs, and a vaccine developed by the University of Oxford, while in a separate trial, Goulder is examining the potential of a different bNAb together with antiretrovirals to see whether it can help more children achieve long-term remission. 'We think that adding the effects of these broadly neutralizing antibodies to antiretrovirals will help us chip away at what is needed to achieve a cure,' says Goulder. 'It's a little bit like with leukemia, where treatments have steadily improved, and now the outlook for most children affected is incredibly good. Realistically in most cases, curing HIV probably requires a few hits from different angles, impacting the way that the virus can grow, and tackling it with different immune responses at the same time to essentially force it into a cul-de-sac that it can't escape from.' Children are also being viewed as the ideal target population for an even more ambitious experimental treatment, a one-time gene therapy that delivers instructions directing the body's own muscle cells to produce a continuous stream of bNAbs, without the need for repeated infusions. Maurico Martins, an associate professor at the University of Florida, who is pioneering this new approach, feels that it could represent a particularly practical strategy for low-income countries where HIV transmission to children is particularly rife, and mothers often struggle to keep their children on repeated medication. 'In regions like Uganda or parts of South Africa where this is very prevalent, you could also give this therapy to a baby right after birth as a preventative measure, protecting the newborn child against acquisition of HIV through breastfeeding and maybe even through sexual intercourse later in life,' says Martins. While Martins also hopes that gene therapy could benefit HIV-infected adults in future, he feels it has more of a chance of initially succeeding in children because their nascent immune systems are less likely to launch what he calls an anti-drug response that can destroy the therapeutic bNAbs. 'It's very difficult for most antibodies to recognize the HIV envelope protein because it's buried deep within a sugar coat,' says Martins. 'To overcome that, these bNAbs carry a lot of mutations and extensions to their arms which allow them to penetrate that sugar coat. But the problem then is that they're often viewed by your own immune system as foreign, and it starts making these anti-bNAb antibodies.' But when Martins tested the therapy in newborn rhesus macaques, it was far more effective. 'We found that the first few days or two weeks after birth comprised a sort of sweet spot for this gene therapy,' he says. 'And that's why this could really work very well in treating and preventing pediatric HIV infections.' Like many HIV scientists, Martins has run into recent funding challenges, with a previous commitment from the National Institutes of Health to support a clinical trial of the novel therapy in HIV-infected children being withdrawn. However, he is hoping that the trial will still go ahead. 'We're now talking with the Gates Foundation to see whether they can sponsor it,' he says. While children still comprise the minority of overall HIV infections, being able to cure them may yield further insights that help with the wider goal of an overall curative therapy. 'We can learn a lot from them because they are different,' says Goulder. 'I think we can learn how to achieve a cure in kids if we continue along this pathway, and from there, that will have applications in adults as well.'
